Overnight closed-loop insulin delivery in young people with type 1 diabetes: A free-living, randomized clinical trial

Diabetes Care

Volumn 37, Issue 5, 2014, Pages 1204-1211

  Hovorka, Roman ^a,b   Elleri, Daniela ^a,b   Thabit, Hood ^a   Allen, Janet M ^a,b   Leelarathna, Lalantha ^a,b   El Khairi, Ranna ^a,b   Kumareswaran, Kavita ^a,b   Caldwell, Karen ^a,b   Calhoun, Peter ^c   Kollman, Craig ^c   Murphy, Helen R ^a   Acerini, Carlo L ^b   Wilinska, Malgorzata E ^a,b   Nodale, Marianna ^a   Dunger, David B ^a,b  

^a INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c JAEB CENTER FOR HEALTH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN ASPART; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; BLOOD GLUCOSE MONITORING; CHILD; CLINICAL ARTICLE; CLOSED LOOP SYSTEM; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE SENSOR; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; MALE; NOCTURNAL HYPOGLYCEMIA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; ADVERSE EFFECTS; BLOOD; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; FEASIBILITY STUDY; GLUCOSE BLOOD LEVEL; INSULIN INFUSION; METABOLISM; TIME; TREATMENT OUTCOME;

ADOLESCENT; BLOOD GLUCOSE; CHILD; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899117172     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2644     Document Type: Article

References (31)

1. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-3176
2. Matyka KA, Crowne EC, Havel PJ, Macdonald IA, Matthews D, Dunger DB. Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Diabetes Care 1999;22:1144-1150 (Pubitemid 29293968)
3. Wood JR, Miller KM, Maahs DM, et al.; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013;36:2035-2037
4. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med 2012;366:1616-1624
5. Phillip M, Danne T, Shalitin S, et al.; Consensus Forum Participants. Use of continuous glucose monitoring in children and adolescents. Pediatr Diabetes 2012;13:215-228
6. Tamborlane WV, Beck RW, Bode BW, et al.; Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucosemonitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008;359:1464-1476
7. Slover RH, Welsh JB, Criego A, et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes 2012;13:6-11
8. Bergenstal RM, Klonoff DC, Garg SK, et al.; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224-232
9. Ly TT, Nicholas JA, Retterath A, LimEM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013;310:1240-1247
10. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010;375:743-751
11. Elleri D, Allen JM, Kumareswaran K, et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 2013;36:838-844
12. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011;342:d1855
13. Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Tech 2010;4:1374-1381
14. Breton M, Farret A, Bruttomesso D, et al.; International Artificial Pancreas Study Group. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012;61:2230-2237
15. Murphy HR, Kumareswaran K, Elleri D, et al. Safety and efficacy of 24-h closed-loop insulin delivery in well-controlled pregnant women with type 1 diabetes: a randomized crossover case series. Diabetes Care 2011;34:2527-2529
16. Dauber A, Corcia L, Safer J, Agus MS, Einis S, Steil GM. Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial. Diabetes Care 2013;36:222-227
17. Sherr JL, Cengiz E, Palerm CC, et al. Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes. Diabetes Care 2013;36:2909-2914
18. Nimri R, Danne T, Kordonouri O, et al. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized cross-over trial. Pediatr Diabetes 2013;14:159-167
19. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 2013;185:297-305
20. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824-833
21. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care 2013;36:1851-1858
22. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014;15:91-99
23. Geoffrey M, Brazg R, Richard W. FreeStyle Navigator continuous glucose monitoring system with TRUstart algorithm, a 1-hour warm-up time. J Diabetes Sci Tech 2011;5:99 - 106
24. Elleri D, Allen JM, Biagioni M, et al. Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes. Pediatr Diabetes 2012;13:449-453
25. Hovorka R, Shojaee-Moradie F, Carroll PV, et al. Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. Am J Physiol Endocrinol Metab 2002;282:E992-E1007 (Pubitemid 34654712)
26. Wilinska ME, Budiman ES, Taub MB, et al. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies. J Diabetes Sci Tech 2009;3:1109-1120
27. Wilinska ME, Chassin LJ, Acerini CL, Allen JM, Dunger DB, Hovorka R. Simulation environment to evaluate closed-loop insulin delivery systems in type 1 diabetes. J Diabetes Sci Tech 2010;4:132-144
28. Kumareswaran K, Elleri D, Allen JM, et al. Meta-analysis of overnight closed-loop randomized studies in children and adults with type 1 diabetes: the Cambridge cohort. J Diabetes Sci Tech 2011;5:1352-1362
29. Hovorka R, Nodale M, Haidar A, Wilinska ME. Assessing performance of closed-loop insulin delivery systems by continuous glucose monitoring: drawbacks and way forward. Diabetes Technol Ther 2013;15:4-12
30. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Prolonged nocturnal hypoglycemia is common during 12 months of continuous glucose monitoring in children and adults with type 1 diabetes. Diabetes Care 2010;33:1004-1008
31. National Paediatric Diabetes Audit Report 2010-11. London, Royal College of Paediatric and Child Care, 2012